Publications
Detailed Information
Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chee Hae | - |
dc.contributor.author | Hwang, In-Chang | - |
dc.contributor.author | Choi, Hong-Mi | - |
dc.contributor.author | Ahn, Chang Ho | - |
dc.contributor.author | Yoon, Yeonyee E. | - |
dc.contributor.author | Cho, Goo-Yeong | - |
dc.date.accessioned | 2022-10-07T00:41:05Z | - |
dc.date.available | 2022-10-07T00:41:05Z | - |
dc.date.created | 2022-09-20 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | International Journal of Cardiology, Vol.364, pp.104-111 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185526 | - |
dc.description.abstract | Background: The differential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in cardiovascular or renal outcomes have not been fully investigated. Methods: Patients with diabetes prescribed SGLT2i or GLP1RA were retrospectively identified. Patients treated with antihyperglycemic medications other than SGLT2i or GLP1RA were used as a control group. Primary outcomes were composite ischemic events (acute coronary syndrome, coronary revascularization, and stroke) and a composite of heart failure and renal events (hospitalization for heart failure, renal death, initiation of renal replacement therapy, and renal admission). Results: During a median 38.7 months of follow-up, the incidence of composite ischemic events tended to be lower in the GLP1RA group (annualized rate 0.82% per person-year) than in the other groups (1.68% per person-year in the SGLT2i group and 1.36% per person-year in the control group). The risk of a composite of heart failure and renal outcomes was significantly lower in the SGLT2i group than in the GLP1RA and control groups (0.86% per person-year, 2.33% per person-year, and 1.48% per person-year, respectively). The SGLT2i group had a slower decline in renal function over time compared to that in other groups. Conclusions: SGLT2i showed more benefits in heart failure and renal outcomes, whereas GLP1RA tended to have more favorable ischemic outcomes. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ijcard.2022.06.027 | - |
dc.citation.journaltitle | International Journal of Cardiology | - |
dc.identifier.wosid | 000850452700026 | - |
dc.identifier.scopusid | 2-s2.0-85133288617 | - |
dc.citation.endpage | 111 | - |
dc.citation.startpage | 104 | - |
dc.citation.volume | 364 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Cho, Goo-Yeong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.